Article Information
History
- August 13, 2021.
Article Versions
- Version 1 (April 12, 2021 - 13:36).
- You are currently viewing Version 2 of this article (August 13, 2021 - 22:31).
- Version 3 (August 20, 2021 - 08:38).
- View Version 4, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Steven A. Kemp1,3,*,
- Oscar Charles1,
- Anne Derache2,
- Collins Iwuji2,5,
- John Adamson2,
- Katya Govender2,
- Tulio de Oliveira2,6,
- Nonhlanhla Okesola2,
- Francois Dabis7,8,
- Darren P. Martin9,
- on behalf of the French National Agency for AIDS and Viral Hepatitis Research (ANRS) 12249 Treatment as Prevention (TasP) Study Group,
- Deenan Pillay1,
- Richard A. Goldstein1 and
- Ravindra K. Gupta2,3
- 1Division of Infection & Immunity, University College London, London, UK
- 2Africa Health Research Institute, Durban, South Africa
- 3Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK
- 4Department of Medicine, University of Cambridge, Cambridge, UK
- 5Research Department of Infection and Population Health, University College London, United Kingdom
- 6KRISP - KwaZulu-Natal Research and Innovation Sequencing Platform, UKZN, Durban, South Africa
- 7INSERM U1219-Centre Inserm Bordeaux Population Health, Université de Bordeaux, France
- 8Université de Bordeaux, ISPED, Centre INSERM U1219-Bordeaux Population Health, France
- 9Department of Integrative Biomedical Sciences, University of Cape Town, South Africa
- ↵*Address for correspondence: Steven A Kemp, Cambridge Institute for Therapeutic Immunology and Infectious Diseases, Jeffrey Cheah Biomedical Centre, Cambridge CB2 0AW, UK, sk2137{at}cam.ac.uk or Ravindra K Gupta, Cambridge Institute for Therapeutic Immunology and Infectious Diseases, Jeffrey Cheah Biomedical Centre, Cambridge CB2 0AW, UK, Rkg20{at}cam.ac.uk
Posted August 13, 2021.
HIV-1 evolutionary dynamics under non-suppressive, 2nd-line protease-inhibitor containing antiretroviral therapy
